These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 27051923)
1. [EVALUATION OF THE PHARMACOKINETIC INTERACTION OF AFOBAZOLE WITH CYP2C9 ENZYME DRUG SUBSTRATE OF CYTOCHROME P450]. Gribakina OG; Kolyvanov GB; Litvin AA; Smirnov VV; Shevchenko RV; Zherdev VP Eksp Klin Farmakol; 2015; 78(12):18-22. PubMed ID: 27051923 [TBL] [Abstract][Full Text] [Related]
2. [In vivo study of the pharmacokinetic interaction of afobazole and losartan (cytochrome CYP2C9 substrate)]. Gribakina OG; Kolyvanov GB; Litvin AA; Zherdev VP; Seredin SB Eksp Klin Farmakol; 2013; 76(3):35-7. PubMed ID: 23767102 [TBL] [Abstract][Full Text] [Related]
3. Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174. Bae JW; Choi CI; Lee HI; Lee YJ; Jang CG; Lee SY Int J Clin Pharmacol Ther; 2012 Sep; 50(9):683-9. PubMed ID: 22735459 [TBL] [Abstract][Full Text] [Related]
4. [In vivo evaluation of the metabolic ratio of CYP2C9 and CYP1A2 drug markers after administration of afobazole in comparison to standard inducers and inhibitors of cytochromes]. Novitskaia IaG; Gribakina OG; Kolyvanov GB; Zherdev VP; Smirnov VV; Seredenin SB Eksp Klin Farmakol; 2013; 76(11):36-9. PubMed ID: 24555232 [TBL] [Abstract][Full Text] [Related]
5. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Kaukonen KM; Olkkola KT; Neuvonen PJ Eur J Clin Pharmacol; 1998 Feb; 53(6):445-9. PubMed ID: 9551703 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761 [TBL] [Abstract][Full Text] [Related]
7. Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1/*1, *1/*2, and *1/*3 individuals. Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA Pharmacotherapy; 2003 Jun; 23(6):720-5. PubMed ID: 12820813 [TBL] [Abstract][Full Text] [Related]
8. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. Choi DH; Li C; Choi JS J Pharm Pharmacol; 2010 Jul; 62(7):908-14. PubMed ID: 20636879 [TBL] [Abstract][Full Text] [Related]
9. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Yang SH; Choi JS; Choi DH Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429 [TBL] [Abstract][Full Text] [Related]
10. Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Choi JS; Choi JS; Choi DH Pharmazie; 2013 Nov; 68(11):882-8. PubMed ID: 24380237 [TBL] [Abstract][Full Text] [Related]
12. Effects of salvianolic acid B and tanshinone IIA on the pharmacokinetics of losartan in rats by regulating the activities and expression of CYP3A4 and CYP2C9. Wang R; Zhang H; Wang Y; Yu X; Yuan Y J Ethnopharmacol; 2016 Mar; 180():87-96. PubMed ID: 26806573 [TBL] [Abstract][Full Text] [Related]
13. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Li Z; Wang G; Wang LS; Zhang W; Tan ZR; Fan L; Chen BL; Li Q; Liu J; Tu JH; Hu DL; Liu ZQ; Zhou HH Xenobiotica; 2009 Oct; 39(10):788-93. PubMed ID: 19604036 [TBL] [Abstract][Full Text] [Related]
14. [Evaluation of pharmacokinetic interaction of aphobazole with CYP1A2 drug-substrate in experiments]. Novitskaia IaG; Litvin AA; Viglinskaia AO; Zherdev VP Eksp Klin Farmakol; 2013; 76(6):30-3. PubMed ID: 24003488 [TBL] [Abstract][Full Text] [Related]
15. Negligible Pharmacokinetic Interaction of Red Ginseng and Losartan, an Antihypertensive Agent, in Sprague-Dawley Rats. Ryu SH; Kim YS; Jang HJ; Kim KB J Toxicol Environ Health A; 2015; 78(20):1299-309. PubMed ID: 26514876 [TBL] [Abstract][Full Text] [Related]
16. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. Yang SH; Cho YA; Choi JS Acta Pharmacol Sin; 2011 Jul; 32(7):967-72. PubMed ID: 21666702 [TBL] [Abstract][Full Text] [Related]
17. [Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves]. Arslanbekova SM; Sychev DA; Kazakov RE; Smirnov VV; Kuznetsova EV; Golukhova EZ Kardiologiia; 2013; 53(12):21-4. PubMed ID: 24800477 [TBL] [Abstract][Full Text] [Related]